Departments of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine Baltimore, MD, USA.
Department of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA 21224.
Pain Med. 2017 Aug 1;18(8):1505-1515. doi: 10.1093/pm/pnw228.
More than 100 million adults in the United States experience chronic pain, and prescription opioids are the third most widely prescribed class of medications. Current opioid overdose prevention efforts almost exclusively target illicit opioid users, and little is known about the experience of overdose among patients being treated for chronic pain (CP) with a prescription opioid.
Patients experiencing CP for three or more months and receiving a prescription opioid for pain management (N = 502) completed a self-report survey that asked questions about opioid overdose history, past 30-day risk factors, and knowledge of opioid overdose, overdose risk, and naloxone.
Approximately one in five CP participants reported experiencing a lifetime overdose. CP participants reported engaging in several behaviors associated with overdose risk and were unlikely to have been trained to administer naloxone. Fewer than 50% of participants answered any knowledge item correctly. The likelihood of having experienced an overdose increased as the scores on the SOAPP-R and DSM-5 opioid use disorder checklist increased, and a SOAPP-R score of 7 or higher or meeting DSM-5 mild opioid use disorder criteria were significantly associated with reporting a lifetime overdose (85% and 84% of participants who experienced an overdose, respectively).
Opioid overdose occurs at a high rate among CP participants, and this group is relatively uninformed about risk factors for overdose. Established SOAPP-R and DSM thresholds provide an opportunity to identify participants at elevated risk for having experienced an opioid overdose. These data support development of additional concentrated efforts to prevent overdose among chronic pain patients.
美国有超过 1 亿成年人患有慢性疼痛,而处方类阿片是第三大广泛使用的药物类别。目前,阿片类药物过量预防工作几乎完全针对非法阿片类药物使用者,而对于正在接受处方类阿片治疗慢性疼痛(CP)的患者的过量经历知之甚少。
经历 CP 三个月或以上且正在接受处方类阿片治疗疼痛管理的患者(N=502)完成了一份自我报告调查,该调查询问了关于阿片类药物过量史、过去 30 天风险因素以及阿片类药物过量、风险和纳洛酮的知识。
大约五分之一的 CP 参与者报告有过一生中经历过一次过量。CP 参与者报告了一些与过量风险相关的行为,并且不太可能接受过纳洛酮给药的培训。不到 50%的参与者正确回答了任何一个知识项目。随着 SOAPP-R 和 DSM-5 阿片类使用障碍检查表得分的增加,经历过过量的可能性增加,而 SOAPP-R 得分达到 7 或更高或符合 DSM-5 轻度阿片类使用障碍标准与报告一生中经历过一次过量显著相关(分别为 85%和 84%经历过过量的参与者)。
在 CP 参与者中,阿片类药物过量的发生率很高,而该群体对过量风险的了解相对较少。既定的 SOAPP-R 和 DSM 阈值为识别经历过阿片类药物过量的高风险参与者提供了机会。这些数据支持制定额外的集中努力,以预防慢性疼痛患者的药物过量。